Dr Gopal Golla

Experienced and driven clinical research professional with 7+ years managing clinical operations across decentralized, device, and pharmaceutical trials with a strong focus on Oncology, Neurology, Ophthalmology, Immunology, Rare Diseases, and medical devices across multiple phases of clinical trials. Proven ability to lead cross-functional teams and execute clinical programs with precision in matrixed, fast-paced environments. Led and managed clinical trials, focusing on various cancer types, including solid tumors and hematologic malignancies, ensuring protocol compliance and adherence to regulatory standards. Experienced in decentralized clinical trial (DCT) strategies, including eConsent, remote monitoring, and digital health integrations. Led monitoring efforts for large, pivotal Phase I-IV global clinical trials, ensuring compliance with ICH-GCP, FDA, and EMA regulations across multiple therapeutic areas. Adept at developing project plans, tracking KPIs, and proactively removing operational barriers to meet contract objectives. Gained deep expertise in neurology clinical trials, particularly in studies related to neurodegenerative diseases such as Alzheimer's and Parkinson's, working closely with neurologists and clinical investigators. Strong background in regulatory compliance with ICH-GCP, FDA, and ISO 14155 standards, ensuring audit readiness and patient safety. Worked on trials involving imaging-based endpoints, ensuring data accuracy and compliance, which is directly applicable to ophthalmology studies that often involve imaging technologies like OCT or retinal photography. Skilled in stakeholder engagement, vendor/CRO oversight, and risk-based monitoring to optimize quality and timeline performance. Coordinated immunology clinical trials, focusing on autoimmune disorders, inflammatory conditions, and immunotherapies, ensuring patient safety and treatment efficacy in these complex therapeutic areas. Recognized for strategic thinking, clear communication, and a proactive, solutions-driven approach to complex clinical operations. Expertise in site monitoring, regulatory compliance (GCP, FDA, ICH, ISO 14155), and data integrity. Specialized in managing rare disease clinical trials, including studies for conditions like Duchenne muscular dystrophy (DMD), cystic fibrosis, and other genetic disorders, addressing the challenges of small patient populations. Led study startup activities, including site selection and feasibility assessments, and obtained central ethics and regulatory approvals, ensuring efficient project kick-offs and timely patient recruitment. Collaborating with investigators to ensure accurate data collection, particularly for ophthalmic endpoints. Adept at cross-functional collaboration with site investigators, engineers, and regulatory teams to ensure trial success. Worked closely with clinical data management teams to ensure data accuracy, proper documentation, and compliance with ICH-GCP guidelines throughout the clinical trial process. Managed clinical site and vendor relationships, ensuring high-quality data collection, on-time deliverables, and budget adherence, particularly in complex therapeutic areas such as rare diseases and immunology. Proven ability to manage pre-market clinical trials (Feasibility & Pivotal), IDE studies, and investigational device accountability. Played an integral role in regulatory submissions, including IND/NDA filings, clinical trial applications (CTAs), and working with regulatory agencies (FDA, EMA) to facilitate trial approvals. Monitoring site compliance with protocols that required retinal imaging and visual acuity testing. Developed and executed patient recruitment strategies, overcoming the challenges of enrolling participants in rare disease and immunology trials and maintaining high retention rates throughout the study period. Ensured prompt and accurate reporting of adverse events (AE) and serious adverse events (SAE), adhering to all regulatory requirements for patient safety and timely issue resolution. Collaborated with cross-functional teams.